Payment overview · 2025
General Payments
$41,780.70
138 reported records · 19 companies
Healthcare provider profile · identity verified
Chad R Christopherson, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · SAN ANTONIO, TX · NPI 1154305365
Verified facts
What the public records show
CMS Open Payments records show Chad R Christopherson, MD received $41,780.70 in general payments during 2025 across 138 reported records.
AngioDynamics, Inc. accounted for 72.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $30,431.58 | 72.8% | 10 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$3,868.88 | 9.3% | 38 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $2,389.27 | 5.7% | 12 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $2,354.34 | 5.6% | 25 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $532.63 | 1.3% | 22 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $467.34 | 1.1% | 4 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $465.31 | 1.1% | 5 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $384.29 | 0.9% | 4 | 2025 |
| InspireMD Ltd | Unresolved — no canonical attribution shown | $298.44 | 0.7% | 2 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $165.40 | 0.4% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $109.84 | 0.3% | 4 | 2025 |
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $64.17 | 0.1% | 2 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $59.79 | 0.1% | 3 | 2025 |
| AtriCure, Inc. | Unresolved — no canonical attribution shown | $55.90 | 0.1% | 1 | 2025 |
| Imperative Care, Inc | Unresolved — no canonical attribution shown | $38.89 | 0.1% | 1 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $31.16 | 0.1% | 1 | 2025 |
| Becton, Dickinson and Company | Unresolved — no canonical attribution shown | $24.83 | 0.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $21.24 | 0.1% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $17.40 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Long term medical supply or device loan | $30,000.00 | 1 |
| Food and Beverage | $8,990.92 | 127 |
| Travel and Lodging | $1,589.78 | 9 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,200.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $30,414.10 | 8 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $2,806.95 | 28 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $2,389.27 | 12 | 2025 |
Source payment records
|
|||||
| NAVITOR Normalized: navitor |
Device | Abbott Laboratories | $1,081.76 | 10 | 2025 |
Source payment records
|
|||||
| TRICLIP Normalized: triclip |
Device | Abbott Laboratories | $635.40 | 7 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $566.58 | 4 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $532.63 | 22 | 2025 |
Source payment records
|
|||||
| COROFLOW Normalized: coroflow |
Device | Abbott Laboratories | $409.63 | 7 | 2025 |
Source payment records
|
|||||
| CGuard Prime Carotid Stent System Normalized: cguard prime carotid stent system |
Device | InspireMD Ltd | $298.44 | 2 | 2025 |
Source payment records
|
|||||
| ENDURANT IIS Normalized: endurant iis |
Device | Medtronic, Inc. | $282.22 | 4 | 2025 |
Source payment records
|
|||||
| DIAMONDBACK CORONARY Normalized: diamondback coronary |
Device | Abbott Laboratories | $227.55 | 1 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $226.16 | 3 | 2025 |
Source payment records
|
|||||
| FFRANGIO Normalized: ffrangio |
Device | Medtronic, Inc. | $213.13 | 2 | 2025 |
Source payment records
|
|||||
| GUIDELINER Normalized: guideliner |
Device | Teleflex LLC | $165.40 | 1 | 2025 |
Source payment records
|
|||||
| EVOQUE Normalized: evoque |
Device | Edwards Lifesciences Corporation | $158.13 | 1 | 2025 |
Source payment records
|
|||||
| Labosys Normalized: labosys |
Device | Philips North America LLC | $149.98 | 1 | 2025 |
Source payment records
|
|||||
| IV Other Normalized: iv other |
Device | Philips North America LLC | $147.77 | 1 | 2025 |
Source payment records
|
|||||
| IGT Devices Systems Undivided Normalized: igt devices systems undivided |
Device | Philips North America LLC | $135.24 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $78.52 | 3 | 2025 |
Source payment records
|
|||||
| Passeo-18 Normalized: passeo 18 |
Device | BIOTRONIK INC. | $64.17 | 2 | 2025 |
Source payment records
|
|||||
| Pulsar-18 T3 Normalized: pulsar 18 t3 |
Device | BIOTRONIK INC. | $64.17 | 2 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $59.79 | 3 | 2025 |
Source payment records
|
|||||
| ATRICLIP LAA EXCLUSION SYSTEM Normalized: atriclip laa exclusion system |
Device | AtriCure, Inc. | $55.90 | 1 | 2025 |
Source payment records
|
|||||
| AtriCure cryoICE Cryoablation System (CRYO2) Normalized: atricure cryoice cryoablation system cryo2 |
Device | AtriCure, Inc. | $55.90 | 1 | 2025 |
Source payment records
|
|||||
| SYNERGY ABLATION SYSTEM Normalized: synergy ablation system |
Device | AtriCure, Inc. | $55.90 | 1 | 2025 |
Source payment records
|
|||||
| SYMPHONY CATHETER Normalized: symphony catheter |
Device | Imperative Care, Inc | $38.89 | 1 | 2025 |
Source payment records
|
|||||
| Coronary Other Normalized: coronary other |
Device | Philips North America LLC | $34.35 | 1 | 2025 |
Source payment records
|
|||||
| General - Vascular Intervention Normalized: general vascular intervention |
Device | Boston Scientific Corporation | $31.32 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE 6/7F VCS Normalized: cardiva vascade 6 7f vcs |
Device | CARDIVA MEDICAL, INC. | $31.16 | 1 | 2025 |
Source payment records
|
|||||
| RotarexS 6 F x 135 cm Normalized: rotarexs 6 f x 135 cm |
Device | Becton, Dickinson and Company | $24.83 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $21.24 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $17.40 | 1 | 2025 |
Source payment records
|
|||||
| ALPHAVAC Normalized: alphavac |
Device | AngioDynamics, Inc. | $15.94 | 1 | 2025 |
Source payment records
|
|||||
| ANGIOVAC Normalized: angiovac |
Device | AngioDynamics, Inc. | $1.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
79 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 262 | 97 |
| Carvedilol | Carvedilol | 229 | 87 |
| Eliquis | Apixaban | 180 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 120 | 49 |
| Atorvastatin Calcium | Atorvastatin Calcium | 118 | 46 |
| Furosemide | Furosemide | 116 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 99 | 43 |
| Amlodipine Besylate | Amlodipine Besylate | 80 | 30 |
| Entresto | Sacubitril/Valsartan | 79 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 66 | 21 |
| Lisinopril | Lisinopril | 66 | 29 |
| Losartan Potassium | Losartan Potassium | 63 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 53 | 20 |
| Amiodarone Hcl | Amiodarone Hcl | 45 | 18 |
| Nitroglycerin | Nitroglycerin | 38 | 20 |
| Ranolazine Er | Ranolazine | 30 | 11 |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Potassium Chloride | Potassium Chloride | 26 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 15 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $41,780.70 · 138 records | AngioDynamics, Inc. | ALPHAVAC, ANGIOVAC, ATRICLIP LAA EXCLUSION SYSTEM, AURYON LASER SYSTEM 100-120 VAC, AtriCure cryoICE Cryoablation System (CRYO2), Barostim Neo System, CARDIVA VASCADE 6/7F VCS, CGuard Prime Carotid Stent System, COREVALVE EVOLUT R, COROFLOW, Coronary Other, DIAMONDBACK CORONARY, ENDURANT IIS, EVOQUE, FFRANGIO, FUROSCIX, GUIDELINER, General - Vascular Intervention, IGT Devices Systems Undivided, IV Other, Indigo System, LEQVIO, Labosys, LifeVest, NAVITOR, Passeo-18, Pulsar-18 T3, RotarexS 6 F x 135 cm, SAPIEN 3 Ultra RESILIA, SYMPHONY CATHETER, SYMPLICITY G3, SYNERGY ABLATION SYSTEM, TRICLIP, WATCHMAN FLX | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novartis Pharmaceuticals Corporation?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error